H.R. 6130

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6130 Introduced in House (IH)]

<DOC>

119th CONGRESS
1st Session
H. R. 6130

To amend title XVIII of the Social Security Act to provide for Medicare 
coverage of blood-based dementia screening tests.

_______________________________________________________________________

IN THE HOUSE OF REPRESENTATIVES

November 19, 2025

Mr. Buchanan (for himself and Mr. Tonko) introduced the following bill; 
which was referred to the Committee on Energy and Commerce, and in 
addition to the Committee on Ways and Means, for a period to be 
subsequently determined by the Speaker, in each case for consideration 
of such provisions as fall within the jurisdiction of the committee 
concerned

_______________________________________________________________________

A BILL

To amend title XVIII of the Social Security Act to provide for Medicare 
coverage of blood-based dementia screening tests.

Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the ``Alzheimer's Screening and Prevention 
Act of 2025'' or the ``ASAP Act''.

SEC. 2. MEDICARE COVERAGE OF ALZHEIMER'S DISEASE AND RELATED DEMENTIAS 
EARLY DETECTION SCREENING TESTS.

(a) Coverage.--Section 1861 of the Social Security Act (42 U.S.C. 
1395x) is amended--
(1) in subsection (s)(2)--
(A) in subparagraph (JJ), by striking the semicolon 
at the end and inserting ``; and''; and
(B) by adding at the end the following new 
subparagraph:
``(KK) Alzheimer's disease and related dementias early 
detection screening tests (as defined in subsection (nnn));''; 
and
(2) by adding at the end the following new subsection:
``(nnn) Alzheimer's Disease and Related Dementias Early Detection 
Screening Tests.--The term `Alzheimer's disease and related dementias 
early detection screening test' means a test furnished to an individual 
for the detection of the pre-symptomatic and early stage of Alzheimer's 
disease or related dementias on or after January 1, 2028, that--
``(1) is cleared under section 510(k), classified under 
section 513(f)(2), or approved under section 515 of the Federal 
Food, Drug, and Cosmetic Act; and
``(2) is--
``(A) a genomic sequencing blood or blood product 
test; or
``(B) such other equivalent test, including a 
single-analyte test, blood test analysis of cell-free 
nucleic acids, multiplex panel test, whole genome 
sequencing, protein expression, whole exome, whole 
transcriptome, and medical imaging (which are based on 
blood, blood products, tissue, urine or other 
biospecimen), as the Secretary determines appropriate 
in providing results comparable to those obtained with 
a test described in subparagraph (A).''.
(b) Payment.--Section 1833(h)(1)(A) of the Social Security Act (42 
U.S.C. 1395l(h)(1)(A)) is amended by inserting ``Alzheimer's disease 
and related dementias early detection screening tests under section 
1861(nnn) and'' after ``including''.
<all>